APA (7th ed.) Citation

Yamada, Y., Takahari, D., Matsumoto, H., Baba, H., Nakamura, M., Yoshida, K., . . . Sugihara, K. (2013). Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial. The lancet oncology, 14(13), 1278-1286. https://doi.org/10.1016/S1470-2045(13)70490-X

Chicago Style (17th ed.) Citation

Yamada, Yasuhide, et al. "Leucovorin, Fluorouracil, and Oxaliplatin Plus Bevacizumab Versus S-1 and Oxaliplatin Plus Bevacizumab in Patients with Metastatic Colorectal Cancer (SOFT): An Open-label, Non-inferiority, Randomised Phase 3 Trial." The Lancet Oncology 14, no. 13 (2013): 1278-1286. https://doi.org/10.1016/S1470-2045(13)70490-X.

MLA (9th ed.) Citation

Yamada, Yasuhide, et al. "Leucovorin, Fluorouracil, and Oxaliplatin Plus Bevacizumab Versus S-1 and Oxaliplatin Plus Bevacizumab in Patients with Metastatic Colorectal Cancer (SOFT): An Open-label, Non-inferiority, Randomised Phase 3 Trial." The Lancet Oncology, vol. 14, no. 13, 2013, pp. 1278-1286, https://doi.org/10.1016/S1470-2045(13)70490-X.